Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Rejects Apple Trade Secret Theft Claims 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Add as a preferred source on Google
PITTSBURGH, March 05, 2018 -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan, Chief Executive Officer, will present a corporate overview and business update at the ROTH Capital Markets Growth Conference, taking place March 11-13 at the Ritz Carlton hotel in Laguna Niguel, California.
30th Annual ROTH Conference
Date: Monday, March 12
Time: 10:30am Pacific Time
Location: Ritz Carlton Hotel, Salon 6
Webcast: http://wsw.com/webcast/roth32/krys/
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.
CONTACT
Ashley R. Robinson
LifeSci Advisors
[email protected]
